iguratimod has been researched along with Sicca Syndrome in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 7 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Hao, W; He, Q; Yang, K; Yu, G; Zeng, L | 1 |
| Chen, H; He, C; Jiang, H; Liu, S; Luo, C; Lyu, T; Qiao, L; Zeng, L; Zhao, Y | 1 |
| Hu, G; Xu, Q; Yang, XY; Yin, S; You, H; Yu, YF | 1 |
| Chen, H; Deng, Y; He, Q; Long, Z; Ren, X; Xiang, W; Yang, K; Zeng, L | 1 |
| Ge, Y; Tian, J; Wang, S; Yang, J; Yu, J | 1 |
| He, X; Hu, C; Jiang, W; Liu, Y; Zhang, L; Zhao, Y | 1 |
| Jiang, H; Liu, L; Shao, Q; Wang, S | 1 |
| Hong, RT; Li, XL; Liu, XC; Shi, H; Song, YL | 1 |
4 review(s) available for iguratimod and Sicca Syndrome
| Article | Year |
|---|---|
A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren's Syndrome.
Topics: Chromones; Humans; Middle Aged; Randomized Controlled Trials as Topic; Sjogren's Syndrome; Sulfonamides | 2022 |
Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis.
Topics: Drug Therapy, Combination; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Methylprednisolone; Sjogren's Syndrome | 2023 |
Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cytokines; Humans; Sjogren's Syndrome | 2023 |
Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature.
Topics: Chemical and Drug Induced Liver Injury; Chromones; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Methylprednisolone; Middle Aged; Sjogren's Syndrome; Sulfonamides | 2018 |
2 trial(s) available for iguratimod and Sicca Syndrome
| Article | Year |
|---|---|
The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
Topics: Chromones; Humans; Severity of Illness Index; Sjogren's Syndrome; Sulfonamides | 2020 |
Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Topics: Adult; Chromones; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Severity of Illness Index; Sjogren's Syndrome; Sulfonamides; Treatment Outcome | 2021 |
2 other study(ies) available for iguratimod and Sicca Syndrome
| Article | Year |
|---|---|
Iguratimod suppresses Tfh cell differentiation in primary Sjögren's syndrome patients through inhibiting Akt/mTOR/STAT3 signaling.
Topics: Cell Differentiation; Humans; Molecular Docking Simulation; Proto-Oncogene Proteins c-akt; Sjogren's Syndrome; STAT3 Transcription Factor; TOR Serine-Threonine Kinases | 2023 |
Effects of iguratimod on inflammatory factors and apoptosis of submandibular gland epithelial cells in NOD mice.
Topics: Animals; Apoptosis; Disease Models, Animal; Inflammation; Mice; Mice, Inbred NOD; Sjogren's Syndrome; Submandibular Gland | 2023 |